Percutaneous Coronary Intervention

Healio and Cardiology Today have compiled a list of the most-read news in CV intervention from TCT 2022.

Long-term P2Y12 inhibition after PCI reduced bleeding at 3 years compared with dual antiplatelet therapy, with no significant differences observed for ischemic events, according to new data from the SMART-CHOICE trial.

BOSTON — PCSK9 inhibition before primary PCI for STEMI, on top of standard statin therapy, significantly lowered LDL at 6 weeks compared with sham control, according to the results of the EPIC-STEMI trial presented at TCT 2022.

BOSTON — After 2 years, PCI with amphilimus-eluting stents was noninferior to PCI with zotarolimus-eluting stents in patients with diabetes, not confirming the potential superiority signal observed at 1 year.

BOSTON — In the Healio video exclusive, Roxana Mehran, MD, discussed late-breaking research presented at TCT 2022, as well as the benefits of convening the meeting in person following the COVID-19 pandemic.

PCI plus optimal medical therapy vs. optimal medical therapy alone in patients with severe LV dysfunction and extensive CAD.

BOSTON — Addition of fractional flow reserve to the classic SYNTAX score enabled researchers to identify patients with multivessel CAD undergoing PCI who would have similar 1-year outcomes as those who received CABG, a speaker reported.

BOSTON — In the all-comers SCAAR registry of patients with left main CAD who underwent revascularization in Sweden, PCI was associated with higher mortality rates compared with CABG.

BOSTON — Quantitative flow ratio-guided decision-making improved outcomes in patients with angina or recent MI vs. a standard angiography-guided strategy, regardless of whether preplanned PCI was performed or not, a speaker reported.

BOSTON — At a median follow-up of 11.8 years, most outcomes did not differ between PCI with an everolimus-eluting stent and CABG in patients with multivessel CAD, according to new data from the BEST trial.